Aarey Drugs & Pharmaceuticals Ltd
Pharmaceuticals & Biotechnology | Small Cap
Aarey Drugs & Pharmaceuticals Ltd, operating within the Healthcare Services sector, demonstrates a mixed financial performance. The company exhibits strong solvency and profitability, indicating a solid financial foundation and efficient operations. However, growth metrics present a challenge, with declines in operating profit, EPS, asset growth, and net income. Liquidity is adequate, but there's room for improvement in managing short-term obligations. While the company shows good asset turnover and inventory management, collection periods for receivables are lengthy, impacting cash flow. Overall, Aarey Drugs & Pharmaceuticals showcases resilience but needs to address growth concerns to ensure long-term sustainability and competitiveness.
Latest Report
View AllThe Latest Reports Are Not Available at the Moment. We’ll Notify You Once They’re Available.
Latest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
- Valuation MetricsNeutral
- Market Metrics
- Stock Reports
- Stock News
- Growth Ratio4.00
- Financial Ratio3.60
- Profitability Ratio8.90
- Efficiency Ratio6.33
- Coverage Ratio4.40
- Solvency Ratio10.00
- Liquidity Ratio6.12
- Peer Assessment
- Management AssessmentBalanced
- Risk AssessmentBalanced
- 1 HourNeutral
- 2 HoursBullish
- 4 HoursBullish
- 1 DayBullish
- 1 WeekNeutral
- 1 MonthNeutral
Aarey Drugs & Pharmaceuticals Ltd, operating within the Healthcare Services sector, demonstrates a mixed financial performance. The company exhibits strong solvency and profitability, indicating a solid financial foundation and efficient operations. However, growth metrics present a challenge, with declines in operating profit, EPS, asset growth, and net income. Liquidity is adequate, but there's room for improvement in managing short-term obligations. While the company shows good asset turnover and inventory management, collection periods for receivables are lengthy, impacting cash flow. Overall, Aarey Drugs & Pharmaceuticals showcases resilience but needs to address growth concerns to ensure long-term sustainability and competitiveness.
Overall Valuation Score
P/E RATIO (TTM)
59.71
Industry Median
28.62
Small Cap Median
27.17
P/E RATIO
59.71
P/B RATIO
1.58
Industry Median
3.17
Small Cap Median
2.62
P/S RATIO
0.50
Industry Median
3.42
Small Cap Median
2.55
Others
PEG RATIO
-5.64
EV/EBITDA RATIO
18.26
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹83.6 as on Jun 20, 2026.
Unlock Live Chart
Please login to view interactive real-time technical charts powered by TradingView.
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
0.00
Today's Low
0.00
Today's High
The company's growth metrics present a mixed picture. While revenue growth is strong, there are declines in operating profit, earnings per share, asset growth, and net income. This suggests challenges in converting revenue growth into higher profits and efficient asset management. The company needs to address these areas to ensure sustainable growth.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 41.67 | -15.01 | -5.49 | 19.7 | -0.42 |
| Operating Profit Growth Rate | 120 | -27.27 | -50 | -25 | 133.33 |
| Earnings Per Share (EPS) Growth | -7.19 | -42.25 | 12.08 | -14.97 | -1.41 |
| Asset Growth Rate | 5.15 | 18.78 | 4.12 | -3.96 | 2.06 |
| Net Income Growth Rate | 0 | -42.86 | 25 | -20 | 0 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
The company's financial ratios present challenges. Adjusted EPS and book value per share are at threshold, while dividend per share is low as the company does not distribute dividends. Cash EPS is at threshold. However, capital expenditures are relatively high, indicating ongoing investments in operational capabilities. The company needs to optimize these financial metrics to ensure long-term financial health.
| Financial Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Adjusted Earnings Per Share (Adjusted EPS) | 2.8 | 1.6 | 1.79 | 1.43 | 1.43 |
| Cash Earnings Per Share (Cash EPS) | 3.6 | 2.4 | 2.5 | 2.14 | 2.5 |
| Book Value Per Share | 45.2 | 46.8 | 47.5 | 49.29 | 53.57 |
| Dividend Per Share (DPS) | 0 | 0 | 0 | 0 | 0 |
| Capital Expenditures (CapEx) | 2.2 | 1 | 0.7 | 5.2 | 12.4 |
Adjusted Earnings Per Share (Adjusted EPS)
Cash Earnings Per Share (Cash EPS)
Book Value Per Share
Dividend Per Share (DPS)
Capital Expenditures (CapEx)
The company shows a good profitability profile. Gross profit margin is solid. Return on capital employed and return on equity are performing, indicating good returns on investments and shareholder equity. However, return on assets is low. Operating and net margins are strong, reflecting effective cost management and profitability.
| Profitability Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Profit Margin | 1.83 | 1.43 | 0.51 | 0.21 | 0.85 |
| Return on Capital Employed (ROCE) | 10 | 6 | 6 | 6 | 6 |
| Return on Equity (ROE) | 6.19 | 3.42 | 3.76 | 2.9 | 2.67 |
| Return on Assets (ROA) | 4.49 | 2.75 | 1.32 | 1.03 | 2.36 |
| Operating Margin | 2.23 | 1.91 | 1.01 | 0.63 | 1.48 |
| Net Margin | 1.42 | 0.95 | 1.26 | 0.84 | 0.85 |
Gross Profit Margin
Return on Capital Employed (ROCE)
Return on Equity (ROE)
Return on Assets (ROA)
Operating Margin
Net Margin
The company's efficiency in asset utilization is a mix of strengths and weaknesses. Fixed asset and inventory turnover ratios are high, indicating efficient use of assets to generate revenue, and quick inventory processing. However, low receivables turnover and extended receivable days suggest slow collection of payments, which impacts cash flow and working capital management. Capital turnover is also low.
| Efficiency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Fixed Asset Turnover Ratio | 35.21 | 29.93 | 30.46 | 29.62 | 18.15 |
| Inventory Turnover Ratio | 30.19 | 19.21 | 12.28 | 11.82 | 10.76 |
| Receivables Turnover Ratio | 3.31 | 2.57 | 2.12 | 2.99 | 3.59 |
| Days Sales in Inventory Ratio | 12.09 | 19 | 29.72 | 30.88 | 33.92 |
| Receivable Days | 110.27 | 142.02 | 172.17 | 122.07 | 101.67 |
| Capital Turnover Ratio | 4.24 | 3.45 | 2.91 | 3.39 | 3.13 |
Fixed Asset Turnover Ratio
Inventory Turnover Ratio
Receivables Turnover Ratio
Days Sales in Inventory Ratio
Receivable Days
Capital Turnover Ratio
The company's coverage ratios indicate mixed performance. The interest coverage ratio is at threshold, suggesting an acceptable ability to cover interest expenses with earnings. However, the equity dividend coverage ratio is low, as the company does not distribute dividends. This could affect investor perception.
| Coverage Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Interest Coverage Ratio | 6 | 3 | 2.25 | 2.2 | 2 |
| Equity Dividend Coverage Ratio |
Interest Coverage Ratio
Equity Dividend Coverage Ratio
The company exhibits strong solvency, indicating a solid long-term financial position. All the solvency metrics, including debt ratio, debt to equity ratio, equity ratio and debt to asset ratio, reveal that the company has a low level of debt and a substantial equity base. This provides financial stability and reduces the risk of financial distress.
| Solvency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Debt Ratio | 0.03 | 0.04 | 0.02 | 0.01 | 0.01 |
| Debt to Equity Ratio | 0.03 | 0.04 | 0.02 | 0.01 | 0.01 |
| Equity Ratio | 0.97 | 0.96 | 0.98 | 0.99 | 0.99 |
| Debt To Asset Ratio | 0.01 | 0.01 | 0.01 | 0.01 | 0 |
Debt Ratio
Debt to Equity Ratio
Equity Ratio
Debt To Asset Ratio
The company's liquidity position reveals strengths and weaknesses. The quick ratio indicates a good ability to meet short-term obligations with its most liquid assets. However, the cash ratio is very low, suggesting a reliance on other current assets besides cash. The current ratio is at average, while the operating cash flow ratio is weak, implying potential difficulties in generating cash from operations to cover current liabilities.
| Liquidity Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Current Ratio | 1.8 | 1.64 | 1.73 | 1.81 | 1.84 |
| Quick Ratio | 1.69 | 1.46 | 1.52 | 1.51 | 1.55 |
| Cash Ratio | 0 | 0.01 | 0.01 | 0.01 | 0.01 |
| Operating Cash Flow Ratio | 0 | -0.01 | -0.02 | 0.07 | 0.07 |
Current Ratio
Quick Ratio
Cash Ratio
Operating Cash Flow Ratio
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Par Drugs & Chemicals Ltd | 7.40 | 8.88 | Undervalued | 17.00 | 10.65 | 13.00 |
| 2 | Infinium Pharmachem Ltd | 6.42 | 26.90 | Neutral | 22.00 | 6.43 | 14.00 |
| 3 | Aarey Drugs & Pharmaceuticals Ltd | 5.73 | 59.71 | Neutral | 7.00 | 1.40 | 4.00 |
| 4 | BPL Ltd | 5.46 | -31.11 | Neutral | -4.82 | -3.00 | -8.55 |
| 5 | Zim Laboratories Ltd | 5.41 | 41.96 | Neutral | 30.00 | 1.11 | 6.00 |
| 6 | Quest Laboratories Ltd | 5.27 | 11.21 | Neutral | 18.00 | 9.16 | 15.00 |
| 7 | Sotac Pharmaceuticals Ltd | 5.27 | 21.26 | Neutral | 18.00 | 4.45 | 6.00 |
| 8 | Lyka Labs Ltd | 4.77 | -23.98 | Neutral | -4.00 | -9.05 | -10.00 |
| 9 | Krebs Biochemicals & Industries Ltd | 4.16 | -5.27 | Highly Undervalued | -4.00 | -12.49 | -4.00 |
| 10 | Nectar Lifescience Ltd | 3.83 | -2.67 | Neutral | -59.00 | -2.95 | -293.00 |
Aarey Drugs & Pharmaceuticals presents a mixed picture of management effectiveness. While there are positive aspects such as sales growth, concerns exist regarding profitability, returns on equity and promoter holding. The sales have grown, but profit margins and returns on equity are low. The decrease in promoter holding from 50.05% to 44.80% may reflect shifting management dynamics or strategic decisions. Overall, the company demonstrates strengths in revenue generation but needs to address profitability to improve overall management effectiveness.
| Category | Metric | Value | Assessment |
|---|---|---|---|
| PROS | Sales Growth (TTM) | 20% | Revenue expansion |
| CONS | Return on Equity (Last Year) | 3% | Low shareholder returns |
| Promoter Holding (Mar 2025) | 44.80% | Reduced promoter confidence |
Financial Performance & Growth
Aarey Drugs & Pharmaceuticals exhibits a mixed performance in financial growth. While sales growth is positive, profitability metrics are weak. The compounded sales growth shows a positive trend, the compounded profit growth is negative. This inconsistency between sales and profit growth raises concerns about the company's efficiency in converting revenue into profit.
| Metric | 2015-2017 | 2018-2020 | 2021-2023 | 2025 |
|---|---|---|---|---|
| Compounded Sales Growth (%) | 35.7% | -2.9% | 8.9% | 19.8% |
| Compounded Profit Growth (%) | -12.5% | 0.3% | -29.8% | -14% |
Capital Efficiency & Returns
The capital efficiency and returns of Aarey Drugs & Pharmaceuticals are low. The ROCE has been consistently low. ROE is also low. The low ROCE and ROE indicate that the company is not effectively utilizing its capital and shareholder funds to generate returns.
| Metric | 2014-2016 | 2017-2019 | 2020-2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| ROCE % | 6.67% | 16% | 9% | 6% | 6% | 6% |
| ROE % | 0.6% | 2.8% | 2.7% | 6% | 6% | 3.82% |
Shareholding & Ownership Structure
The shareholding pattern of Aarey Drugs & Pharmaceuticals indicates a moderate level of promoter confidence. The promoter holding has decreased over the years from 53.40% in Mar 2017 to 44.80% in Mar 2025. The FII holding has also decreased from 3.92% in Mar 2023 to 2.34% in Mar 2025. There is a corresponding increase in public holding.
| Metric | Mar 2017 | Mar 2019 | Mar 2021 | Mar 2023 | Mar 2025 |
|---|---|---|---|---|---|
| Promoter Holding (%) | 53.40% | 50.44% | 49.38% | 50.05% | 44.80% |
| FII Holding (%) | 0.00% | 15.04% | 7.12% | 3.92% | 2.34% |
Aarey Drugs & Pharmaceuticals exhibits a moderate risk profile. Segment volatility is indicated by fluctuating quarterly sales growth. Exposure to interest rate risk is present due to borrowings. Overall, these factors suggest a need for cautious monitoring and strategic risk management.
Segment performance volatility
Aarey Drugs & Pharmaceuticals experiences volatility in its segment performance, as indicated by the fluctuating quarterly sales growth. The YOY Sales Growth % varies significantly across quarters. High variability in sales growth can lead to uncertainties in revenue forecasting and overall financial planning.
| Quarter | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| YOY Sales Growth % | -32.54% | -43.36% | 35.45% | -24.17% | 29.14% | -48.61% |
Foreign exchange or interest rate exposure
Aarey Drugs & Pharmaceuticals has exposure to interest rate risk. The company has borrowings, making it susceptible to changes in interest rates. Interest payments have varied over the years, reflecting the impact of borrowing costs on profitability. This exposure could impact the company's profitability and financial stability.
| Metric | 2014-2016 | 2017-2019 | 2020-2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Interest | 1.33 | 2.67 | 2 | 3 | 4 | 4 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 1081.93Bullish
- SMA 2081.21Bullish
- SMA 5079.21Bullish
- EMA 1082.01Bullish
- EMA 2081.26Bullish
- EMA 5080.01Bullish
- DEMA 1082.79Bearish
- DEMA 2082.50Bearish
- DEMA 5081.10Bullish
- TEMA 1082.89Bearish
- TEMA 2082.86Bearish
- TEMA 5082.34Bearish
- MACD0.95Bullish
- ADX22.07Weak Trend
- IndicatorValueSignal
- RSI53.99Neutral
- CCI166.72Overbought
- ROC 91.27Bullish
- ROC 141.40Bullish
- ROC 254.50Bullish
- Stoch K76.22Neutral
- Stoch D72.41Neutral
- IndicatorValueSignal
- BB Upper83.96Neutral
- BB Middle81.21Neutral
- BB Lower78.46Neutral
- ATR2.14High Volatility
- IndicatorValueSignal
- MFI75.17Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 2 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 1081.47Bullish
- SMA 2080.11Bullish
- SMA 5078.83Bullish
- EMA 1081.46Bullish
- EMA 2080.52Bullish
- EMA 5079.80Bullish
- DEMA 1082.56Bearish
- DEMA 2081.84Bullish
- DEMA 5079.53Bullish
- TEMA 1082.81Bearish
- TEMA 2082.60Bearish
- TEMA 5080.75Bullish
- MACD1.05Bullish
- ADX17.51Weak Trend
- IndicatorValueSignal
- RSI55.65Neutral
- CCI146.45Overbought
- ROC 91.71Bullish
- ROC 144.11Bullish
- ROC 258.71Bullish
- Stoch K75.69Neutral
- Stoch D75.88Neutral
- IndicatorValueSignal
- BB Upper83.70Neutral
- BB Middle80.11Neutral
- BB Lower76.52Neutral
- ATR2.49High Volatility
- IndicatorValueSignal
- MFI66.82Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 4 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
- IndicatorValueSignal
- SMA 1080.09Bullish
- SMA 2079.41Bullish
- SMA 5080.59Bullish
- EMA 1080.29Bullish
- EMA 2079.77Bullish
- EMA 5080.22Bullish
- DEMA 1081.22Bullish
- DEMA 2079.95Bullish
- DEMA 5080.16Bullish
- TEMA 1081.70Bullish
- TEMA 2081.15Bullish
- TEMA 50N/AN/A
- MACD0.29Bullish
- ADX22.54Weak Trend
- IndicatorValueSignal
- RSI58.08Neutral
- CCI181.04Overbought
- ROC 93.87Bullish
- ROC 142.87Bullish
- ROC 259.37Bullish
- Stoch K75.22Neutral
- Stoch D76.11Neutral
- IndicatorValueSignal
- BB Upper82.25Neutral
- BB Middle79.41Neutral
- BB Lower76.57Neutral
- ATR3.27High Volatility
- IndicatorValueSignal
- MFI82.06Overbought
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 33 Technical Indicators From The 1 Day Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 1079.67Bullish
- SMA 2079.23Bullish
- SMA 5082.68Bullish
- SMA 10074.91Bullish
- SMA 20076.73Bullish
- EMA 1080.31Bullish
- EMA 2080.46Bullish
- EMA 5079.78Bullish
- EMA 10077.50Bullish
- EMA 20074.18Bullish
- DEMA 1080.96Bullish
- DEMA 2079.73Bullish
- DEMA 5082.43Bullish
- DEMA 10081.11Bullish
- DEMA 20080.61Bullish
- TEMA 1082.43Bullish
- TEMA 2079.15Bullish
- TEMA 5082.16Bullish
- TEMA 10082.16Bullish
- TEMA 20080.84Bullish
- MACD-0.38Bullish
- ADX23.50Weak Trend
- IndicatorValueSignal
- RSI57.42Neutral
- CCI163.58Overbought
- ROC 148.05Bullish
- ROC 25-8.43Bearish
- Stoch K87.20Overbought
- Stoch D80.63Overbought
- IndicatorValueSignal
- BB Upper83.71Neutral
- BB Middle79.23Neutral
- BB Lower74.76Neutral
- ATR4.35High Volatility
- IndicatorValueSignal
- MFI78.80Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 21 Technical Indicators From The 1 Week Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 2074.82Bullish
- SMA 5075.05Bullish
- EMA 2077.38Bullish
- EMA 5072.80Bullish
- DEMA 2080.71Bearish
- DEMA 5080.03Bearish
- TEMA 2081.87Bearish
- TEMA 5080.53Bearish
- MACD2.69Bullish
- ADX19.39Weak Trend
- IndicatorValueSignal
- RSI52.05Neutral
- CCI22.21Neutral
- ROC 148.65Bullish
- ROC 2513.63Bullish
- Stoch K60.37Neutral
- Stoch D65.88Neutral
- IndicatorValueSignal
- BB Upper96.34Neutral
- BB Middle74.82Neutral
- BB Lower53.30Neutral
- ATR8.95Low Volatility
- IndicatorValueSignal
- MFI66.50Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 25 Technical Indicators From The 1 Month Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 671.97Bullish
- SMA 1274.26Bullish
- SMA 2463.94Bullish
- EMA 675.22Bullish
- EMA 1271.69Bullish
- EMA 2465.18Bullish
- DEMA 678.02Bearish
- DEMA 1278.36Bearish
- DEMA 2476.37Bullish
- TEMA 678.13Bearish
- TEMA 1278.53Bearish
- TEMA 24N/AN/A
- MACD12.46Bullish
- ADX22.48Weak Trend
- IndicatorValueSignal
- RSI54.98Neutral
- CCI154.78Overbought
- ROC 2549.12Bullish
- ROC 5088.15Bullish
- Stoch K69.22Neutral
- Stoch D62.01Neutral
- IndicatorValueSignal
- BB Upper97.52Neutral
- BB Middle64.85Neutral
- BB Lower32.18Neutral
- ATR18.20Low Volatility
- IndicatorValueSignal
- MFI62.12Neutral